Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders

References

• Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. Biomedicine & Pharmacotherapy. 2004; 58(1):39–46. 14739060
   PubMed Web of Science ®Google Scholar
• Amor S, Puentes F, Baker D, Van Der Valk PJI. Inflammation in neurodegenerative diseases. Immunology 2010;129(2):154–169.
   Google Scholar
• Koo EH, Lansbury PT, Kelly JWJ. Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proceedings of the National Academy of Sciences. 1999;96(18):9989–9990.
   Google Scholar
• Radad K, Gille G, Liu L, Rausch WD. Use of ginseng in medicine with emphasis on neurodegenerative disorders. Journal of Pharmacological Sciences 2006;100(3):175–186.
   Google Scholar
• Maiti P, Dunbar GJ. Use of curcumin, a natural polyphenol for targeting molecular pathways in treating age-related neurodegenerative diseases. International journal of molecular sciences 2018;19(6):1637.
   Google Scholar
• Shanmugam M, Rane G, Kanchi M, et al. The multifaceted role of curcumin in cancer prevention and treatment. Molecules 2015;20(2):2728–2769.
   Google Scholar
• Ahmadi F, Ghasemi-Kasman M, Ghasemi S, et al. Induction of apoptosis in hela cancer cells by an ultrasonic-mediated synthesis of curcumin-loaded chitosan–alginate–sTPP nanoparticles. Int J Nanomedicine. 2017;12:8545. 29238191
   PubMed Web of Science ®Google Scholar
• Moustapha A, Pérétout P, Rainey N, et al. Curcumin induces crosstalk between autophagy and apoptosis mediated by calcium release from the endoplasmic reticulum, lysosomal destabilization and mitochondrial events. Cell Death Discovery. 2015;1:15017. 27551451
   PubMed Web of Science ®Google Scholar
• Rainey N, Motte L, Aggarwal BB, Petit P. Curcumin hormesis mediates a cross-talk between autophagy and cell death. Cell death & Disease 2015, 6:e2003.
   Google Scholar
• Zorofchian Moghadamtousi S, Abdul Kadir H, Hassandarvish P, Tajik H, Abubakar S, Zandi KJ. A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed Research International 2014(2014):1–12. 
   Google Scholar
• Mukhopadhyay A, Basu N, Ghatak N, Gujral PJA. Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents and actions 1982;12(4):508–515.
   Google Scholar
• Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. Journal of Biological Chemistry 2005;280(7):5892–5901.
   Google Scholar
• Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Mol Targets Ther Uses Curcumin Health Dis. 2007;595: 1–75.
   Google Scholar
• Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Mol Targets Ther Uses Curcumin Health Dis. 2007;595: 105–125.
   Google Scholar
• Thiyagarajan M, Sharma SS. Neuroprotective effect of curcumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life sciences 2004;74(8):969–985.
   Google Scholar
• Wang X-S, Zhang Z-R, Zhang -M-M, et al. Neuroprotective properties of curcumin in toxin-base animal models of Parkinson’s disease: a systematic experiment literatures review. BMC complementary and alternative medicine 2017;17(1):412.
   Google Scholar
• Anand P, Kunnumakkara AB, Newman RA, Aggarwal BBJ. Bioavailability of curcumin: problems and promises. Molecular pharmaceutics 2007;4(6):807–818.
   Google Scholar
• Yallapu M, Jaggi M, Chauhan SJC. Curcumin nanomedicine: a road to cancer therapeutics. Current pharmaceutical design 2013;19(11):1994–2010.
   Google Scholar
• Shehzad A, Rehman G, Lee YS. Curcumin in inflammatory diseases. Biofactors 2013;39(1):69–77.
   Google Scholar
• Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Mol Targets Ther Uses Curcumin Health Dis. 2007;595: 197–212.
   Google Scholar
• Hamaguchi T, Ono K, Yamada M. Curcumin and Alzheimer’s disease. CNS Neurosci Ther. 2010;16(5):285–297. 20406252
   PubMed Web of Science ®Google Scholar
• Xie L, Li X-K, Takahara S. Curcumin has bright prospects for the treatment of multiple sclerosis. Int Immunopharmacol. 2011;11(3):323–330. 20828641
   PubMed Web of Science ®Google Scholar
• Mythri B, Srinivas Bharath M. Curcumin: a potential neuroprotective agent in Parkinson’s disease. Curr Pharm Des. 2012;18(1):91–99. 22211691
   PubMed Web of Science ®Google Scholar
• Dende C, Meena J, Nagarajan P, Nagaraj VA, Panda AK, Padmanaban GJ. Nanocurcumin is superior to native curcumin in preventing degenerative changes in experimental cerebral malaria. Scientific reports 2017;7(1):10062.
   Google Scholar
• Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 2014;35(10):3365–3383. 24439402
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Nagesh PKB, Jaggi M, Chauhan SC. Therapeutic applications of curcumin nanoformulations. Aaps J. 2015;17(6):1341–1356. 26335307
   PubMed Web of Science ®Google Scholar
• Mouhieddine TH, Itani MM, Nokkari A, et al. Nanotheragnostic applications for ischemic and hemorrhagic strokes: improved delivery for a better prognosis. Current neurology and neuroscience reports 2015;15(1):505.
   Google Scholar
• Szymusiak M, Hu X, Plata PAL, Ciupinski P, Wang ZJ, Liu YJ. Bioavailability of curcumin and curcumin glucuronide in the central nervous system of mice after oral delivery of nano-curcumin. International journal of pharmaceutics 2016;511(1):415–423.
   Google Scholar
• Ghalandarlaki N, Alizadeh AM, Ashkani-Esfahani SJ. Nanotechnology-applied curcumin for different diseases therapy. Biomed Research International 2014;1–23.
   Google Scholar
• Yallapu MM, Jaggi M, Chauhan SCJ. Curcumin nanoformulations: a future nanomedicine for cancer. Drug discovery today: 2012;17(1–2):71–80.
   Google Scholar
• Naksuriya O, Okonogi S, Schiffelers RM, Hennink WEJB. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 2014;35(10):3365–3383.
   Google Scholar
• Maiti P, Paladugu L, Dunbar GLJB. Solid lipid curcumin particles provide greater anti-amyloid, anti-inflammatory and neuroprotective effects than curcumin in the 5xFAD mouse model of Alzheimer’s disease. BMC neuroscience. 2018;19(1):7.
   Google Scholar
• Yao EC, Xue L. Therapeutic effects of curcumin on Alzheimer’s disease. Advances in Alzheimer's disease. 2014;3(04):145.
   Google Scholar
• Tang M, Taghibiglou C. The mechanisms of action of curcumin in Alzheimer’s disease. Journal of Alzheimer's disease. 2017;58(4):1003–1016.
   Google Scholar
• Cheng KK, Yeung CF, Ho SW, Chow SF, Chow AH, Baum L. Highly stabilized curcumin nanoparticles tested in an in vitro blood–brain barrier model and in Alzheimer’s disease Tg2576 mice. The AAPS journal. 2013;15(2):324–336.
   Google Scholar
• Lie D-C, Colamarino SA, Song H-J, et al. Wnt signalling regulates adult hippocampal neurogenesis. Nature. 2005;437(7063):1370.
   Google Scholar
• Tiwari SK, Agarwal S, Seth B, et al. Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer’s disease model via canonical Wnt/β-catenin pathway. ACS nano. 2013;8(1):76–103.
   Google Scholar
• Huo X, Zhang Y, Jin X, Li Y, Zhang LJ, Biology PB. A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid β aggregation in Alzheimer’s disease. Journal of Photochemistry and Photobiology B: Biology. 2019;190:98–102.
   Google Scholar
• Meng F, Asghar S, Gao S, et al. A novel LDL-mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer’s disease. Colloids and Surfaces B: Biointerfaces. 2015;134:88–97.
   Google Scholar
• Shi S, Liang D, Chen Y, et al. Gx‐50 reduces β‐amyloid‐induced TNF‐α, IL‐1β, NO, and PGE2 expression and inhibits NF‐κB signaling in a mouse model of Alzheimer’s disease. European journal of immunology. 2016;46(3):665–676.
   Google Scholar
• Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer’s disease animal models. Journal of Alzheimer's disease. 2004;6(4):367–377.
   Google Scholar
• Barbara R, Belletti D, Pederzoli F, et al. Novel curcumin loaded nanoparticles engineered for blood-brain barrier crossing and able to disrupt Abeta aggregates. International journal of pharmaceutics. 2017;526(1–2):413–424.
   Google Scholar
• Beach TG, Walker R, McGeer EJG. Patterns of gliosis in Alzheimer’s disease and aging cerebrum. Glia. 1989;2(6):420–436.
   Google Scholar
• Huang N, Lu S, Liu X-G, Zhu J, Wang Y-J, Liu R-TJO. PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Aβ generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer’s disease mice. Oncotarget. 2017;8(46):81001.
   Google Scholar
• Djiokeng Paka G, Doggui S, Zaghmi A, et al. Neuronal uptake and neuroprotective properties of curcumin-loaded nanoparticles on SK-N-SH cell line: role of poly (lactide-co-glycolide) polymeric matrix composition. Molecular phrmaceutics. 2015;13(2):391–403.
   Google Scholar
• Hamaguchi T, Ono K, Yamada M. Curcumin and Alzheimer's disease. CNS neuroscience & therapeutics. 2010;16(5):285–29720406252
   PubMed Web of Science ®Google Scholar
• Huang H-C, Tang D, Xu K, Jiang Z-F. Transduction S. Curcumin attenuates amyloid-β-induced tau hyperphosphorylation in human neuroblastoma SH-SY5Y cells involving PTEN/Akt/GSK-3β signaling pathway. Journal of Receptors and Signal Transduction. 2014;34(1):26–37.
   Google Scholar
• Fan S, Zheng Y, Liu X, et al. Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer’s disease. Drug delivery. 2018;25(1):1091–1102.
   Google Scholar
• Yan MH, Wang X, Zhu XJ. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radical Biology  and Medicine. 2013;62:90–101.
   Google Scholar
• Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nature Reviews Neurology. 2008;4(11):600.
   Google Scholar
• Siddique YH, Naz F, Jyoti SJ. Effect of curcumin on lifespan, activity pattern, oxidative stress, and apoptosis in the brains of transgenic Drosophila model of Parkinson’s disease. Biomed research international 2014;1–6.
   Google Scholar
• Ganesan P, Ko H-M, Kim I-S, Choi D-K. Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson’s disease models. International journal of nanomedicine 2015;10:6757.
   Google Scholar
• Bollimpelli VS, Kumar P, Kumari S, Kondapi AKJ. Neuroprotective effect of curcumin-loaded lactoferrin nano particles against rotenone induced neurotoxicity. Neurochemistry international 2016;95:37–45.
   Google Scholar
• Siddique YH, Khan W, Singh BR, Naqvi AH. Synthesis of alginate-curcumin nanocomposite and its protective role in transgenic Drosophila model of Parkinson’s disease. ISRN pharmacology. 2013;1–8.
   Google Scholar
• Nisi Zhang FY, Liang X, Wu M, et al. Localized delivery of curcumin into brain with polysorbate 80-modified cerasomes by ultrasound-targeted microbubble destruction for improved Parkinson’s disease therapy. Theranostics. 2018;8(8):2264.
   Google Scholar
• Kundu P, Das M, Tripathy K, Sahoo SK. Delivery of dual drug loaded lipid based nanoparticles across the blood–brain barrier impart enhanced neuroprotection in a rotenone induced mouse model of Parkinson’s disease. ACS chemical neuroscience. 2016;7(12):1658–1670.
   Google Scholar
• Hwang OJ. Role of oxidative stress in Parkinson’s disease. Experimental neurobiology. 2013;22(1):11–17.
   Google Scholar
• Rakotoarisoa M, Angelov B, Garamus VM, Angelova AJ. Curcumin-and fish oil-loaded spongosome and cubosome nanoparticles with neuroprotective potential against H2O2-induced oxidative stress in differentiated human SH-SY5Y cells. ACS Omega. 2019;4(2):3061–3073.
   Google Scholar
• Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes & development 1999;13(22):2905–2927.
   Google Scholar
• Sookhaklari R, Geramizadeh B, Abkar M, Moosavi MJA. The neuroprotective effect of BSA-based nanocurcumin against 6-OHDA-induced cell death in SH-SY5Y cells. Avicenna Journal of Phytomedicine. 2018;9(2):92–100.
   Google Scholar
• Greene LA, Levy O, Malagelada CJC. Akt as a victim, villain and potential hero in Parkinson’s disease pathophysiology and treatment. Cellular and molecular neurobiology. 2011;31(7):969–978.
   Google Scholar
• Sandhir R, Yadav A, Mehrotra A, Sunkaria A, Singh A, Sharma SJ. Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington’s disease. Neuromolecular  medicine. 2014;16(1):106–118.
   Google Scholar
• Campbell G, Mahad DJ. Neurodegeneration in progressive multiple sclerosis. Cold Spring Harbor perspectives in medicine. 2018;8(10):a028985.
   Google Scholar
• Yan J, Greer JJC, Targets ND-D. NF. κB, a potential therapeutic target for the treatment of multiple sclerosis. CNS & Neurological Disorders-Drug Targets. 2008;7(6):536–557.
   Google Scholar
• Xie L, Li X-K, Takahara SJ. Curcumin has bright prospects for the treatment of multiple sclerosis. International immunopharmacology: 2011;11(3):323–330.
   Google Scholar
• Mohajeri M, Sadeghizadeh M, Najafi F, Javan MJN. Polymerized nano-curcumin attenuates neurological symptoms in EAE model of multiple sclerosis through down regulation of inflammatory and oxidative processes and enhancing neuroprotection and myelin repair. Neuropharmacology. 2015;99: 156–167.
   Google Scholar
• Naeimi R, Safarpour F, Hashemian M, et al. Curcumin-loaded nanoparticles ameliorate glial activation and improve myelin repair in lyolecithin-induced focal demyelination model of rat corpus callosum. Neuroscience letters. 2018;674:1–10.
   Google Scholar
• Dhir AJ. Curcumin in epilepsy disorders. Phytotherapy Research 2018;32(10):1865–1875.
   Google Scholar
• Drion C, van Scheppingen J, Arena A, et al. Effects of rapamycin and curcumin on inflammation and oxidative stress in vitro and in vivo—in search of potential anti-epileptogenic strategies for temporal lobe epilepsy. Journal of neuroinflammation 2018;15(1):212.
   Google Scholar
• Bertoncello KT, Aguiar GPS, Oliveira JV, Siebel AM. Micronization potentiates curcumin’s anti-seizure effect and brings an important advance in epilepsy treatment. Scientific reports 2018;8(1):2645.
   Google Scholar
• Khadrawy YA, Sawie HG, Hosny EN. Neuroprotective effect of curcumin nanoparticles against rat model of status epilepticus induced by pilocarpine. J Complementary Integr Med. 2018;15:3.
   Google Scholar
• Ahmad N, Ahmad I, Umar S, Iqbal Z, Samim M, Ahmad FJ. PNIPAM nanoparticles for targeted and enhanced nose-to-brain delivery of curcuminoids: UPLC/ESI-Q-ToF-MS/MS-based pharmacokinetics and pharmacodynamic evaluation in cerebral ischemia model. Drug delivery. 2016;23(7):2095–2114.
   Google Scholar
• Aminirad A, Mousavi SE, Fakhraei N, Mousavi SM, Rezayat SM. The role of nitric oxide in anticonvulsant effect of nanocurcumine on pentylenetetrazole-induced seizure in mice. Neuroscience letters. 2017;651:226–231.
   Google Scholar
• Agarwal NB, Jain S, Nagpal D, et al. Liposomal formulation of curcumin attenuates seizures in different experimental models of epilepsy in mice. Fundamental & clinical pharmacology. 2013;27(2):169–172.
   Google Scholar
• Mansoor SR, Hashemian M, Khalili-Fomeshi M, Ashrafpour M, Moghadamnia AA, Ghasemi-Kasman MJ. Upregulation of klotho and erythropoietin contributes to the neuroprotection induced by curcumin-loaded nanoparticles in experimental model of chronic epilepsy. Brain research bulletin. 2018;142:281–288.
   Google Scholar
• Hashemian M, Anissian D, Ghasemi-Kasman M, et al. Curcumin-loaded chitosan-alginate-STPP nanoparticles ameliorate memory deficits and reduce glial activation in pentylenetetrazol-induced kindling model of epilepsy. Prog Neuro-Psychopharmacol Bio Psychiatry. 2017;79:462–471.
   PubMed Web of Science ®Google Scholar
• de Girolamo L, Lucarelli E, Alessandri G, et al. Mesenchymal stem/stromal cells: a new’’cells as drugs’’paradigm. Efficacy Crit Aspects Cell Ther. 2013;19(13):2459–2473.
   Google Scholar
• Chapel A, Bertho JM, Bensidhoum M, et al. Mesenchymal stem cells home to injured tissues when co‐infused with hematopoietic cells to treat a radiation‐induced multi‐organ failure syndrome. The Journal of Gene Medicine: A cross disciplinary journal for research on the science of gene transfer and its clinical applications. 2003;5(12):1028–1038.
   Google Scholar
• Tripodo G, Chlapanidas T, Perteghella S, et al. Mesenchymal stromal cells loading curcumin-INVITE-micelles: a drug delivery system for neurodegenerative diseases. Colloids and Surfaces B: Biointerfaces. 2015;125:300–308.
   Google Scholar
• Dolati S, Ahmadi M, Aghebti-Maleki L, et al. Nanocurcumin is a potential novel therapy for multiple sclerosis by influencing inflammatory mediators. Pharmacological Reports. 2018;70(6):1158–1167.
   Google Scholar
• Moore C, Kennedy T, Antel J, Bar-Or A, Dhaunchak AJ. MicroRNA dysregulation in multiple sclerosis. Frontiers in genetics. 2013;3:311.
   Google Scholar
• Sun L, Liu B, Lin Z, et al. MiR-320a acts as a prognostic factor and Inhibits metastasis of salivary adenoid cystic carcinoma by targeting ITGB3. Molecular cancer. 2015;14(1):96.
   Google Scholar
• Du C, Liu C, Kang J, et al. MicroRNA miR-326 regulates T H-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nature immunology:. 2009;10(12):1252.
   Google Scholar
• Renjie W, Haiqian LJ. MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5. Cancer letters. 2015;356(2):568–578.
   Google Scholar
• Dolati S, Aghebati‐Maleki L, Ahmadi M, et al. Nanocurcumin restores aberrant miRNA expression profile in multiple sclerosis, randomized, double-blind, placebo-controlled trial. Journal of cellular physiology. 2018;233(7):5222–5230.
   Google Scholar
• Segal BM. Th17 cells in autoimmune demyelinating disease. Seminars in Immunopathology. 2010;32(1):71–77.
   Google Scholar
• Aranami T, Yamamura TJ. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergology International. 2008;57(2):115–120.
   Google Scholar
• Jadidi‐Niaragh F, Mirshafiey AJ. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scandinavian journal of immunology. 2011;74(1):1–13.
   Google Scholar
• Xie L, Li X-K, Funeshima-Fuji N, et al. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. International immunopharmacology: 2009;9(5):575–581.
   Google Scholar
• Zhao G, Liu Y, Yi X, et al. Curcumin inhibiting Th17 cell differentiation by regulating the metabotropic glutamate receptor-4 expression on dendritic cells. International immunopharmacology: 2017;46:80–86.
   Google Scholar
• Dolati S, Ahmadi M, Rikhtegar R, et al. Changes in Th17 cells function after nanocurcumin use to treat multiple sclerosis. International immunopharmacology. 2018;61:74–81.
   Google Scholar
• Zozulya AL, Wiendl HJ. The role of regulatory T cells in multiple sclerosis. Nature Reviews Neurology. 2008;4(7):384.
   Google Scholar
• Dolati S, Babaloo Z, Ayromlou H, et al. Nanocurcumin improves regulatory T-cell frequency and function in patients with multiple sclerosis. J Neuroimmunol. 2019;327:15–21. 30683426
   PubMed Web of Science ®Google Scholar
• Ahmadi M, Agah E, Nafissi S, et al. Safety and efficacy of nanocurcumin as add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a pilot randomized clinical trial. Neurotherapeutics 2018;15:1–9.
   Google Scholar
• Kaur IP, Bhandari R, Bhandari S, Kakkar VJ. Potential of solid lipid nanoparticles in brain targeting. Journal of Controlled release. 2008;127(2):97–109.
   Google Scholar
• Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer’s disease. Journal of Controlled release. 2005;108(2–3):193–214.
   Google Scholar
• Vega-Villa KR, Takemoto JK, Yáñez JA, Remsberg CM, Forrest ML, Davies N. Clinical toxicities of nanocarrier systems. Advanced drug delivery reviews. 2008;60(8):929–938.
   Google Scholar